Discover our latest insights. 

Leqembi® (lecanemab) was approved to treat Alzheimer’s disease in January, 2023 under the FDA’s Accelerated Approval process for diseases with an unmet need for treatment.1 The manufacturers, Eisai pharmaceuticals, plan to submit data for full FDA approval by the end of March 2023.

Here, we answer some common questions about Leqembi and summarize what is known about its safety and effectiveness. Patients and their families should speak with their physician and weigh the potential benefits and risks before deciding whether to seek treatment with Leqembi.

Many people have experienced colds or flu-like illnesses already this winter. Experts are monitoring the levels and continued spread of these viruses, including flu, COVID-19, and RSV. This article will answer common …

As expected in the winter months, the flu virus spreads throughout our communities. Small children, the elderly, and immune compromised people are at higher risk for complications or serious illness from the …

It’s a frightening thought. You’ve fallen off a bike and injured yourself, but the scan that was supposed to assess for damage to the ribcage discovered a mass in your right lung. …

Cancer is sometimes referred to as a “disease of aging.” For the most part, this is an apt description. People over the age of 65 represent 16% of the population but comprise …

Not all cancers are created equal. Some cancers, when caught early, boast a cure rate above 90%1. Others are especially difficult. Among the most challenging is a brain cancer called glioblastoma. Despite …